Primary Sclerosing Cholangitis damages and blocks bile ducts inside and outside the liver. While the cause is not known, genes, immune system problems, bacteria and viruses may play roles in the development of the disease.
Current Studies:
|
PROGRESS
Enrolling: Yes
Principal Investigator: Dr. Craig Lammert
Duration: 1 visit
Patient Population: Patients with PSC with ERCP, MRCP or liver biopsy.
|
Contact:
Kelsey Green
(317) 278-9292
greenke@iu.edu
|
|
Mayo RC2
Enrolling: Yes
Principle Investigator: Dr. Craig Lammert
Duration: 1 visit
Patient Population: PSC with at least 6 month biochemical presence of chronic cholangitis, must not have NASH.
|
Contact:
Kelsey Green
(317) 278-9292
greenke@iu.edu
|
|
PSC CALID
Enrolling: Yes
Principle Investigator: Dr. Craig Lammert
Duration: 1 visit per year / 20 years
Patient Population: PSC/Pre-Transplant with no history of concomitant liver disease.
|
Contact:
Kelsey Green
(317) 278-9292
greenke@iu.edu
|
|
Gilead PSC (P2 & P3)
Enrolling: Yes
Principle Investigator: Dr. Raj Vuppalanchi
Duration: 104 weeks
Patient Population: Non-cirrhotic large duct PSC
Drug: Oral GS9674 (Cilofexor)
|
Contact:
Mandy Cruz
(317) 278-6215
mandcruz@iu.edu
|
Closed Studies:
|
Intercept 207 OSC Study
Enrolling: No
Duration: 6 months with optional 2-year LTSE
Primary Outcomes measured: Evaluate the effects of OCA on ALP in subjects; evaluate the effects of OCA on safety in subjects with PSC
Drug(s): obeticholic acid and placebo
|
|
NGM 15-106 PSC Study
Enrolling: No
Duration: 22 weeks total, 12 week treatment period
Primary Outcomes measured: The mean and percent change in ALP from Baseline to Week 12
Drug(s): NGM282 or Placebo, 1:1:1 Ratio. Daily subcutaneous injection
|